MYD88 and diffuse large B-cell lymphoma: Among the strengths of our study stands out the fact that this is the first study evaluating the significance of mutated MYD88 and TP53 in DLBCL patients in Egypt through extracting a liquid biopsy and measuring their sensitivity and specificity to correlate their prognostic impact.